Skip to Content



View full screen / Print PDF » Download PDF ⇩


Powder and solvent for solution for injection
Human coagulation factor IX
Read all of this leaflet carefully before you start using this medicine.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, please ask your doctor or your pharmacist.
• This medicine has been prescribed for you. Do not pass it on to others.
It may harm them, even if their symptoms are the same as yours.
• If any of the side effects gets serious, or if you notice any side effects
not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
1. What Haemonine 500 / Haemonine 1000 is and what it is used for
2. Before you use Haemonine 500 / Haemonine 1000
3. How to use Haemonine 500 / Haemonine 1000
4. Possible side effects
5. How to store Haemonine 500 / Haemonine 1000
6. Further information
Haemonine 500 / Haemonine 1000 is presented as a powder and a solvent
for solution for injection. Each vial of Haemonine 500 contains 500 IU (international units) of human coagulation factor IX. In a separate vial, 5 ml
water for injections are provided. Each vial of Haemonine 1000 contains
1000 IU (international units) of human coagulation factor IX. In a separate
vial, 10 ml water for injections are provided. After reconstitution of the dry
substance in the water for injections the product contains 100 IU human
coagulation factor IX per ml.
The specific activity of Haemonine 500 / Haemonine 1000 is ≥ 70 IU/mg

Haemonine 500 / Haemonine 1000 is being prescribed to stop or prevent
bleeding because of a lack of factor IX (Haemophilia B) in your blood. Thus,
Haemonine 500 / Haemonine 1000 as a coagulation factor IX preparation
belongs to the pharmacotherapeutic group of antihaemorrhagics. Factor IX
is a protein that is part of the body‘s natural way of forming clots to stop
bleeding. If it is absent or low in your blood, you will suffer from blood coagulation problems which may lead to bleeding in joints, muscles or internal
organs. You may have this condition from birth or acquire it later in life. The
administration of Haemonine 500 / Haemonine 1000 can compensate for
this deficiency.
185342 001

Do not use Haemonine 500 / Haemonine 1000:
• if you are allergic (hypersensitive) or have had any reactions to coagulation factor IX, to any of the other ingredients of Haemonine 500 / Haemonine 1000
(these are listed in section 6 of this leaflet) or to heparin.
Usually, if you are allergic (hypersensitive) to Haemonine 500 / Haemonine 1000
it will show up within the first applications. The early signs of hypersensitivity
reactions include reddening of the skin, nettle rash, itching over the entire body,
swelling of lips and tongue, breathing difficulties, tightness of the chest, wheezing, drop in blood pressure, loss of consciousness, which can progress to severe
allergic reactions. If you detect one or more of the symptoms listed above in yourself, call your doctor instantly.
Take special care with Haemonine 500 / Haemonine 1000:
• Before you use Haemonine 500 / Haemonine 1000 you should tell your doctor
if you know that you have a risk of thrombosis or you have had thromboembolic complications in the past, if you suffer from liver disease or if a surgery is
planned. These are conditions that increase your risk of developing internal blood
clots, even if you have not been injured. If you are unsure, you should discuss this
with your doctor.
• When medicines are made from human blood or plasma, certain measures are
put in place to prevent infections being passed on to patients. These include careful selection of blood and plasma donors to make sure those at risk of carrying
infections are excluded, and the testing of each donation and pools of plasma
for signs of virus/infections. Manufacturers of these products also include steps
in the processing of the blood or plasma that can inactivate or remove viruses.
Despite these measures, when medicines prepared from human blood or plasma
are administered, the possibility of passing on infection cannot totally be excluded. This also applies to any unknown or emerging viruses or other types of
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for
the non-enveloped hepatitis A virus. The measures taken may be of limited value
against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection
may be serious for pregnant women (fetal infection) and for individuals whose
immune system is depressed or who have some types of anaemia (e.g. sickle cell
disease or haemolytic anaemia).
Your doctor may recommend that you consider vaccination against hepatitis A
and B if you regularly/repeatedly receive human plasma-derived factor IX products.
• It is strongly recommended that every time you receive a dose of Haemonine
500 / Haemonine 1000 the name and batch number of the product are recorded
in order to maintain a record of the batches used.

Taking other medicines
Please tell your doctor if you are taking, or have recently taken, any other medicines
including medicines obtained without a prescription.
No interactions of Haemonine 500 / Haemonine 1000 with other medicinal products are known.
There are insufficient data to recommend the use of Haemonine 500 / Haemonine
1000 in children less then 6 years of age.
Pregnancy and breast-feeding
Haemophilia B in women is rare. Therefore there is no experience regarding the use
of Haemonine 500 / Haemonine 1000 during pregnancy and breast-feeding.
If you are pregnant, planning a family, or breast-feeding ask your doctor or pharmacist for advice before taking any medicine. If you have already told your doctor then
follow any instructions that may have been given to you.
Driving and using machines
No effects on the ability to drive or use machines have been observed.
Important information about some of the ingredients of Haemonine 500 /
Haemonine 1000
This medicinal product contains a maximum of 4.9 mmol (113 mg) sodium per
standard dose of 2,000 IU. To be taken into consideration by patients on a controlled sodium diet.
Always use Haemonine 500 / Haemonine 1000 exactly as your doctor has told you.
You should check with your doctor or pharmacist if you are not sure.
Haemonine 500 / Haemonine 1000 treatment should be started by a doctor who
has experience in the treatment of haemophilia.
Dosage and Frequency of Administration
The amount of Haemonine 500 / Haemonine 1000 you need to use depends on
your weight, the severity of your haemophilia, the site and severity of your bleed,
and the need to prevent bleeding, for example before dentistry or an operation.
Your doctor will calculate the dose of Haemonine 500 / Haemonine 1000 and how
often you need to inject it to obtain the correct levels in your blood.
Factor IX products rarely require to be administered more than once daily.
The number of units of factor IX administered is expressed in International Units
(IU), which are related to the current WHO standard for factor IX products. Factor
IX activity in plasma is expressed either as a percentage (relative to normal human
plasma) or in International Units (relative to an International Standard for factor
IX in plasma).

One International Unit (IU) of factor IX activity is equivalent to that quantity of factor IX in one ml of normal human plasma. The calculation of the required dosage
of factor IX is based on the empirical finding that 1 IU factor IX per kg body weight
raises the plasma factor IX activity by 1-2 % of normal activity. The required dosage
is determined using the following formula:
Required units = body weight (kg) x desired factor IX rise (%) (IU/dl) x 0.8
In the case of the following haemorrhagic events, the factor IX activity should not
fall below the given plasma activity level (in % of normal or in IU/dl) in the corresponding period. The following table can be used to guide dosing in bleeding
episodes and surgery:
Degree of haemorrhage/ Factor IX level
Type of surgical procedure required (%)
Early haemarthrosis,
muscle bleeding or oral

Frequency of doses (hours)/
Duration of therapy (days)

20 - 40

Repeat every 24 hours. At least
1 day, until the bleeding episode as
indicated by pain is resolved or
healing is achieved.

More extensive
muscle bleeding or

30 - 60

Repeat infusion every 24 hours for
3 - 4 days or more until pain and
acute disability are resolved.

Life threatening

60 - 100

Repeat infusion every 8 to 24 hours
until threat is resolved.

30 - 60
including tooth extraction
80 - 100
(pre- and postoperative)

Every 24 hours, at least 1 day, until
healing is achieved.
Repeat infusion every 8 to 24 hours
until adequate wound healing, then
therapy for at least another 7 days
to maintain a factor IX activity of
30 to 60% (IU/dl).

For long term prophylaxis against bleeding in patients with severe haemophilia B,
the usual doses are 20 to 30 IU of factor IX per kilogram of body weight at intervals
of 3 to 4 days. In some cases, especially in younger patients, shorter dosage intervals
or higher doses may be necessary.
It is recommended to not exceed a maximal infusion rate of 5 ml/min.

If you have the impression that the effect of Haemonine 500 / Haemonine 1000 is
too weak, talk to your doctor. You may have developed antibodies to factor IX (see
Possible Side Effects).
If you use more Haemonine 500 / Haemonine 1000 than you should
No symptoms of overdose with human coagulation factor IX have been reported.
Instructions for use
Haemonine 500 / Haemonine 1000 is given by injection into a vein. If you have
been prescribed Haemonine 500 / Haemonine 1000 to use at home, your doctor or
haemophilia centre nurse will have to make sure that you know how to use it.
If you are in any doubt about injecting Haemonine 500 / Haemonine 1000, go back
to your doctor or Haemophilia Centre for more advice and training before attempting to give yourself any treatment. Follow the directions given to you by your doctor or haemophilia nurse.
During the preparation and injection of Haemonine 500 / Haemonine 1000, it is
important to use sterile conditions.
Haemonine 500 / Haemonine 1000 must not be mixed with other medicinal products.
Only the provided injection set should be used, otherwise treatment may not be
efficient due to factor IX adsorption to the internal surfaces of some other injection

Fig. 2

Fig. 4

Fig. 6

Fig. 7

Dissolution of the concentrate:
• Warm the solvent (water for injections) and powder to room
temperature (max. 35°C) in the unopened vials and maintain
this temperature. If a water bath is used for warming, make
Fig. 1
sure that the water does not come into contact with the caps
or stoppers of the vials.
• Remove the caps from both vials to expose the central portions of the rubber stoppers (Fig. 1).
• Clean the stoppers with a disinfectant.
• Pull off the closure of the packaging of the transfer system
pack (Fig. 2). With the water bottle standing upright, place
Fig. 3
the open side of the pack (blue part of the transfer system)
onto the water bottle (Fig. 3).
• Remove the packaging. This exposes the transparent part of
the transfer system.
• Turn the combination of transfer system and water vial upside down and, with the vial of dry powder standing upright,
push the transparent part of the transfer system into the dry
powder vial (Fig. 4). The vacuum present in the dry powder
vial causes the water to run into this vial (Fig. 5). Unscrew the
Fig. 5
blue part of the transfer system together with the water vial
(Fig. 6). Gently rocking the vial helps to dissolve the powder.
Do not shake; there should be no foam. The solution should
be clear or slightly opalescent.
• The solution ready for use should be used immediately after
dissolving. Do not use solutions that are cloudy or have deposits.
• Once you have dissolved the powder, screw the enclosed
syringe with its Luer-Lock connector onto the substrate vial
with the transparent part of the transfer system (Fig. 7). This
will allow you to draw the dissolved preparation into the syringe.
• Carefully unscrew the bottle with the transparent part of
the transfer system and inject the injection preparation
slowly into a vein using the enclosed butterfly needle. You
should inject slowly (2 - 3 ml/minute).
• After the butterfly needle has been used, it can be made
safe with the protective cap.

Any unused product or waste material should be disposed of in accordance with
local requirements.
If you have any further questions on the use of the product, ask your doctor or pharmacist.

Like all medicines, Haemonine 500 / Haemonine 1000 can cause side effects, although not everybody gets them.
The following side effects have been reported:
• Nephrotic syndrome (a disorder where the kidneys are damaged) has been reported in haemophilia B patients with a history of allergic reaction.
• Patients with haemophilia B may develop neutralising antibodies (inhibitors)
to factor IX. This may mean that your bleeding cannot be adequately controlled
by application of Haemonine 500 / Haemonine 1000. If this happens contact
your haemophilia centre. In addition, you may also have an increased risk of allergic reactions if you have antibodies to factor IX.
• There is a small risk of thromboembolic episodes (blood clots).
• All medicines can cause allergic reactions or non-specific hypersensitivity reactions although serious reactions are very rare (less than 1 user in 10,000). Any
sudden wheeziness, difficulty in breathing, tightness of the chest, swelling of the
eyelids, face or lips, rash or itching (especially affecting your whole body), chills,
flushing, fever, headache, hives, hypotension, tiredness, nausea, restlessness, rapid heartbeat, tingling or vomiting should be reported to a doctor immediately.
• Haemonine 500 / Haemonine 1000 may contain traces of heparin which may
cause allergic reactions and reduced blood cell counts which may affect the
blood clotting system. Patients with a history of heparin-induced allergic reactions should avoid the use of heparin-containing medicines.
For the evaluation of undesirable reactions of Haemonine, the following frequencies were used:
Very common:
Very rare:

affects more than 1 user in 10
affects 1 to 10 users in 100
affects 1 to 10 users in 1,000
affects 1 to 10 users in 10,000
affects less than 1 user in 10,000

The following adverse reactions have been reported from patients in clinical studies (1,493 exposure days):
MedDRA Standard System Organ Class
General disorders and administration site
Respiratory, thoracic and mediastinal

Adverse reactions


Feeling cold


Dyspnoe (breathing


If any of the side effects gets serious, or if you notice any side effects not listed in
this leaflet, please tell your doctor or pharmacist.

Keep out of the reach and sight of children.
Keep the vials in the outer carton in order to protect them from light.
Haemonine 500 / Haemonine 1000 should not be stored above 25°C.
Do not freeze.
The product, once opened or dissolved, should be used immediately.
Do not use Haemonine 500 / Haemonine 1000 after the expiry date which is stated
on the label and the outer carton. The expiry date refers to the last day of that
Medicines should not be disposed of via wastewater or household waste. Ask your
pharmacist how to dispose of medicines no longer required. These measures will
help to protect the environment.
What Haemonine 500 / Haemonine 1000 contains:
The active substance is human coagulation factor IX. Each vial of Haemonine 500
contains 500 IU of human coagulation factor IX. Each vial of Haemonine 1000 contains 1000 IU of human coagulation factor IX.
The other ingredients are arginine, lysine, sodium chloride, and sodium citrate.
Water for injections
What Haemonine 500 / Haemonine 1000 looks like and contents of the pack
Powder and solvent for solution for injection. After dissolving the powder in the
provided water for injections, the Haemonine 500 / Haemonine 1000 solution
must be clear or slightly opalescent without any visible particles.
1 package Haemonine 500 contains:
• 1 glass vial with powder
• 1 glass vial with 5 ml water for injections
• 1 disposable syringe (5 ml)
• 1 double filter transfer system
• 1 butterfly cannula
1 package Haemonine 1000 contains:
• 1 glass vial with powder
• 1 glass vial with 10 ml water for injections
• 1 disposable syringe (10 ml)
• 1 double filter transfer system
• 1 butterfly cannula

Marketing Authorisation Holder and Manufacturer:
Biotest Pharma GmbH
Landsteinerstrasse 5
63303 Dreieich
Phone: +49 6103 801-0
Fax: +49 6103 801-150
Local representative in the UK:
Biotest (UK) Ltd.
28 Monkspath Business Park
Highland Road
West Midlands B90 4NZ
Phone: 0121 733 3393
Fax: 0121 733 3066
This medicinal product is authorised in the Member States of the EEA under the
following names:
Haemonine® 100 I.E./ml
Germany: Haemonine® 500 and 1000
Haemonine® 500 and 1000
HaemoBionine® 100 UI/ml
Haemonine® 500 and 1000
This leaflet was last approved in 12/2008.

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.